venice [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
An anonymous [[survey]] of 11 multiple-choice questions about management of[[ aneurysmal subarachnoid hemorrhage]] (aSAH) patients with [[antiplatelet]] use before the initial [[hemorrhage]] was distributed to the international panel of attendees of the [[European Association of Neurosurgical Societies]] ([[EANS]]) annual meeting in [[Venice]], Italy at 1-5 October 2017.

A total of 258 (54%) completed [[survey]]s were returned. In about 80%, the departments of neurosurgery and neurology were responsible for acute management of aSAH patients, whereas in 15% the [[intensive care unit]]. Department [[guideline]]s were present in 32%. In 65%, the responders always stop the antiplatelet agent at admission and in 4.3% are [[thrombocyte]]s always transfused. When a [[guideline]] is present, the neurospecialists consider thrombocyte transfusion more often (83% vs. 65% p=0.02).

The survey among mainly European neurosurgeons show that there is a significant variability in the management of aSAH patients who have been using antiplatelets before the initial hemorrhage. These findings emphasize the importance of the development of evidence-based guidelines for management of patients with aSAH and antiplatelet use before the initial hemorrhage
((Sebök M, Keller E, van Niftrik CHB, Regli L, Germans MR. Management of
aneurysmal subarachnoid hemorrhage patients with antiplatelet use before the
initial hemorrhage: an international survey. World Neurosurg. 2018 Aug 24. pii:
S1878-8750(18)31877-1. doi: 10.1016/j.wneu.2018.08.094. [Epub ahead of print]
PubMed PMID: 30149168.
)).